A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium

Sridhar, Srikala S.; Winquist, Eric; Eisen, Andrea; Hotte, Sébastien J.; McWhirter, Elaine; Tannock, Ian F.; Mukherjee, Som D.; Wang, Lisa; Blattler, Chantale; Wright, John J.; Moore, Malcolm J.

doi:10.1007/s10637-010-9408-4

Cited by 75 publications

(40 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sorafenib is a TKI that blocks cellular proliferation via the ERK pathway and angiogenesis via the VEGF pathway. A first-line trial in chemona€ ve patients showed no ORs, a TTP of 1.9 months, and MS of only 5.9 months, consistent with second-line findings (55,56). A study of GC plus sorafenib showed significant toxicity (57).…”

Section: Anti-vegf Therapysupporting

confidence: 57%

New Directions for Biologic Targets in Urothelial Carcinoma

Richter

Sridhar

2012

Molecular Cancer Therapeutics

Self Cite

View full text Add to dashboard Cite

Urothelial carcinoma remains an important oncologic problem with significant morbidity and mortality. This article provides an overview of the current status of treatment of urothelial carcinoma, with an update on current trials and recent American Society of Clinical Oncology abstracts. As an alternative to focusing on the metastatic setting, we take a broad look at drug development to date, as it spans from early disease to advanced disease in the context of emerging molecular data. This approach allows us to show that each stage involves key considerations based on emerging evidence regarding molecular biology, stage-specific novel endpoints, and rational patient selection that may help further trial designs in the future. Key issues, such as neoadjuvant versus adjuvant perioperative chemotherapy, approaches to salvage second-line therapy in the metastatic setting, and treatment of elderly and cisplatin-ineligible patients, are discussed. New paradigms in clinical research, including novel endpoints, upfront rational patient selection, biomarkers, and trial design, are also addressed. Mol Cancer Ther; 11(6); 1226-35. Ó2012 AACR.

show abstract

Section: Anti-vegf Therapysupporting

confidence: 57%

New Directions for Biologic Targets in Urothelial Carcinoma

Richter

Sridhar

2012

Molecular Cancer Therapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although some positive preclinical studies have been reported, no satisfactory results in terms of clinical benefit have been obtained by the use of VEGFR-TKIs in bladder cancer [78][79][80][81][82][83]. A better knowledge of the mechanisms of VEGFR-TKI-induced cell death may represent a major step forward in identifying potential target for drug resistance.…”

Section: Resistance To Vegf/vegfr Inhibitorsmentioning

confidence: 99%

Emerging concepts on drug resistance in bladder cancer: Implications for future strategies

Massari

Santoni

Ciccarese

et al. 2015

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…Thus, several trials with sunitinib, sorafenib and pazopanib have been performed (21)(22)(23)(24). Sunitinib is preclinically active against urothelial carcinoma (25).…”

Section: Commentsmentioning

confidence: 99%

Combination of gemcitabine and carboplatin in urothelial cancer patients unfit for cisplatin due to impaired renal or cardiac function

Sella

Kovel

2012

Int. braz j urol.

View full text Add to dashboard Cite

show abstract

A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium

Abstract: Sorafenib does not show sufficient activity as a single agent in first-line metastatic urothelial cancer to warrant further investigation.

Cited by 75 publications

References 23 publications

New Directions for Biologic Targets in Urothelial Carcinoma

New Directions for Biologic Targets in Urothelial Carcinoma

Emerging concepts on drug resistance in bladder cancer: Implications for future strategies

Combination of gemcitabine and carboplatin in urothelial cancer patients unfit for cisplatin due to impaired renal or cardiac function

Contact Info

Product

Resources

About